EMERYVILLE, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. today announced positive results for PEP005 (ingenol mebutate) Gel in REGION-I, its Australian and US based Phase III actinic (solar) keratosis (AK) clinical trial for the treatment of lesions on non-head locations, which include the trunk and extremities. AK is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated.
